Peptide businesses are not being terminated at random. The pattern is consistent because the category conflicts with the risk rules used by many mainstream payment providers.
A processor may approve the legal entity, switch on card acceptance and allow transactions to run for weeks or months. Then a catalogue scan, website review, transaction-monitoring alert or partner audit identifies the product category. The account is restricted, funds may be held, and the merchant is asked to find another provider.
That sequence creates the false impression that the business was eligible and later became problematic. In many cases, the original onboarding never assessed the catalogue properly. The account was accepted through a generic route that was not built to support peptide sales.
Stable peptide payment processing starts with a different approach. The provider must review the products, claims, customer types, fulfilment, jurisdictions, transaction values and previous processing history before the account goes live. The setup must be placed with underlying partners that understand what the business sells and have agreed to support it.
Vellis acts as an authorized provider for eligible peptide suppliers, manufacturers and distributors. Vellis works with underlying acquiring and banking partners, manages setup end to end and remains the direct point of contact. You work with Vellis.
The Scale of Peptide Payment Processing Terminations
Peptide merchants sit inside one of the most systematically refused areas of payment processing. The problem is not simply that the products are technical or unfamiliar. Mainstream risk frameworks commonly restrict or prohibit the categories into which many peptide catalogues fall: research chemicals, unapproved products, injectable products, regulated health products and items marketed with therapeutic or body-performance claims.
That creates a structural mismatch. A generic processor is designed to approve conventional retail quickly and investigate exceptions later. A peptide business needs the opposite: detailed review before launch and ongoing management after approval.
The risk becomes more visible when several features appear together:
- A catalogue containing compounds widely associated with human use, even where pages state “research use only”
- Product descriptions that refer to recovery, healing, weight management, hormone response, muscle growth or anti-ageing
- Vials, dosage language, administration references or before-and-after claims
- High average order values or sudden wholesale transactions
- Cross-border sales involving multiple entities, fulfilment locations or settlement currencies
- Limited processing history, recent domain changes or inconsistent company information
- Previous account closures that were not fully explained during onboarding
None of these factors should be hidden. Hiding them usually makes the next termination more likely. The provider needs an accurate operating picture so the account can be assessed and placed correctly.
This is why repeated applications through standard online forms rarely solve the problem. The merchant changes the provider but keeps the same weak onboarding route. The result is another temporary approval followed by another review.
The Specific Compounds Most Likely to Trigger a Review
Risk teams and catalogue-screening systems do not read a peptide website like a scientist or specialist buyer. They look for product names, claims, formats and combinations associated with restricted activity.
Four names create particularly strong signals: BPC-157, TB-500, CJC-1295 and Ipamorelin.
BPC-157 is commonly associated online with recovery and tissue-related claims. TB-500 is frequently presented in similar performance and recovery contexts. CJC-1295 and Ipamorelin are often connected with growth-hormone-related positioning. When these compounds appear alongside dosage language, injectable formats or consumer-facing claims, a processor may conclude that the live business differs materially from the low-risk description submitted during onboarding.
The important point is not that one keyword automatically determines the outcome. Risk systems assess the whole context:
- What the product page says
- Whether the item is sold to businesses, institutions or individual consumers
- Whether research-use positioning is supported consistently across the website
- Whether the merchant makes health, treatment or performance claims
- How the product is packaged and fulfilled
- Whether customer support content discusses personal administration
- Which countries receive the products
- Whether the catalogue disclosed at onboarding matches the live catalogue
Changing a spelling, hiding a page from navigation or moving a product into a separate collection does not change the underlying activity. It may instead create an undisclosed-catalogue problem.
A stable setup requires the provider to see the complete catalogue. That includes products with low sales, password-protected wholesale ranges, planned launches and compounds sold through invoices rather than the public checkout.
The Termination Playbook: What Actually Happens
Most peptide terminations follow a recognisable sequence.
1. The account is accepted
The merchant submits a broad business description such as laboratory supplies, biotechnology products or health-related e-commerce. The initial review focuses on the entity, owners, website and expected volume. The full catalogue may receive little scrutiny.
2. Processing begins normally
Payments are approved, settlements arrive and the merchant assumes the category has been accepted. Volume grows, advertising expands or larger wholesale orders begin.
3. A risk event triggers deeper review
The trigger may be a scheduled website scan, a product-name match, a large transaction, a change in chargeback activity, a customer complaint, a partner audit or a manual review of the merchant’s marketing.
4. The provider requests information
The merchant may be asked for invoices, supplier records, licences, product documentation, fulfilment evidence, marketing explanations, processing statements and clarification of previous terminations. Response deadlines can be short.
5. Processing or payouts are restricted
New payments may be paused, settlement may be delayed or a reserve may be applied while the review continues. The business is now managing cash flow and underwriting at the same time.
6. The account is closed
Where the provider or its underlying partner does not support the product category, better documentation may not reverse the decision. The review is identifying a placement problem that existed from the start.
7. The merchant applies elsewhere under pressure
Urgency leads to another incomplete application, an inaccurate business description or acceptance of weak commercial terms. The cycle repeats.
The best time to prevent termination is before the first transaction. Once the account is frozen, the merchant has less time, less leverage and fewer options.
What Can and Cannot Be Changed About the Business
Some changes improve account stability because they make the operation easier to underwrite. Others are cosmetic and create additional risk.
Merchant Category Code (MCC) Coding Must Be Accurate
A merchant category code should reflect the actual business model. It is not a workaround for prohibited products. Selecting a softer code may reduce questions temporarily, but it creates a mismatch between the approved classification and the live activity. That mismatch becomes serious during a later review.
The business descriptor should be recognisable
The descriptor shown on customer statements should connect clearly to the trading name or website. A confusing descriptor increases disputes and customer complaints. It should not be used to conceal the peptide business.
Catalogue structure can improve clarity
Separate research supply, wholesale, custom manufacturing and other genuine business lines where they operate differently. Use accurate product descriptions, customer eligibility rules and supporting documentation. The purpose is to make the model clear, not to hide products from the provider.
Website claims matter
Remove unsupported medical, treatment, recovery or performance claims. Ensure terms, disclaimers, product pages, support content and advertising present the same intended use. A disclaimer does not neutralise contradictory sales copy.
Reserve arrangements can address financial exposure
A rolling reserve or delayed settlement may help an underlying partner manage refund, chargeback or fulfilment exposure. It cannot make an unsupported product category acceptable. Reserves solve financial risk, not policy incompatibility.
Processing history should be explained
Previous closures, holds and chargeback issues should be disclosed with dates, reasons and corrective action. The provider needs to distinguish a category mismatch from fraud, excessive disputes or operational failure. The only hard eligibility exclusion Vellis identifies is the MATCH list.
Practical Steps to Avoid Another Termination
A merchant that has already lost two or more accounts should stop treating the next application as a form-filling exercise.
Start with a termination audit. Collect closure notices, review requests, processing statements, reserve information, chargeback reports and correspondence. Identify whether each termination resulted from category policy, undisclosed products, marketing claims, transaction behaviour, fulfilment problems, disputes or a MATCH-related issue.
Then prepare a complete underwriting pack:
- Company, ownership and director documents
- Full product catalogue, including wholesale and planned products
- Product sourcing, manufacturing and supplier evidence
- Customer profile and eligibility rules
- Website, advertising and claim review
- Fulfilment locations, delivery times and tracking procedures
- Expected monthly volume, average ticket and maximum transaction value
- Processing history, refunds, chargebacks and previous closures
- Sales geographies, currencies and settlement requirements
- Licences, registrations or supporting legal documentation where relevant
The application, website and transaction plan should describe the same business. Do not apply as a small domestic research supplier if the real plan includes international consumer sales, high-value wholesale orders and rapid catalogue expansion.
Build a change-control process after launch. New compounds, markets, entities, websites, sales channels and material increases in ticket size should be discussed before they appear in live activity.
For a wider operational framework, read how to choose a payment processor for peptide operations.
Choosing a Payment Processor for a Peptide Business
Approval speed is a weak selection criterion. A provider that can activate the account quickly without reviewing the catalogue may simply be postponing the rejection.
Ask six questions before signing.
Does the provider understand the sector?
The provider should be able to discuss catalogue review, research-use positioning, wholesale flows, high-value orders, fulfilment evidence, reserves and material product changes without treating the business as generic e-commerce.
Will the full catalogue be reviewed before placement?
The answer should include public pages, invoice-only products, wholesale ranges and planned launches. Partial disclosure produces partial underwriting.
Is the provider authorized and clear about partner roles?
The provider should explain which responsibilities it manages and which sit with underlying acquiring or banking partners. Avoid any structure in which nobody owns the client relationship once a review begins.
Will you have a direct account contact?
Peptide merchants need a person who understands the original application and can coordinate document requests and escalation. A generic support queue is not enough when settlements are restricted.
How are previous terminations and MATCH status handled?
A credible provider asks about both before submission. A closure by one processor does not automatically mean the merchant is on MATCH, so status should be verified rather than assumed. The provider should not promise to erase processing history or bypass network records.
Can the setup support the real geography and payment flow?
Vellis supports global operations excluding OFAC-listed countries, subject to review and partner approval. The proposed route should match customer locations, fulfilment, entities, currencies, average order values and sales channels. Businesses selling internationally should also review building payment infrastructure for cross-border peptide distribution.
Commercial terms also matter. Review pricing, reserves, settlement timing, transaction limits, refund handling, chargeback support, contract terms and closure procedures. Stability is not created by accepting any proposal. It comes from a setup whose underwriting, economics and operating rules fit the business.
What Working With an Authorized Provider Like Vellis Looks Like
Vellis begins with the operation, not a simplified category label.
The review covers the legal entity, ownership, full catalogue, intended use, customer types, website claims, fulfilment, processing history, expected volumes, order values, sales channels, jurisdictions and settlement requirements. Previous closures are assessed directly so the next setup does not repeat the same failure.
Vellis then works with relevant underlying acquiring and banking partners to structure an appropriate route for an eligible business. Vellis is not a bank or an acquirer and should not be positioned as the direct provider of the underlying infrastructure. In some instances, Vellis may act as a referral agent.
The client relationship remains clear: you work with Vellis. Vellis manages the setup end to end, coordinates documentation and partner questions, and remains the direct point of contact after launch.
That relationship matters because peptide processing is not static. Catalogues change. Wholesale clients create larger tickets. New markets add currencies and fulfilment routes. Advertising can change how products are presented. A stable account needs a process for reviewing those changes before they become unexplained risk signals.
No responsible provider can guarantee that an account will never be reviewed. Reviews are part of payment processing. The goal is to make sure the account was built on full disclosure, placed with suitable partners and supported by records that can answer a review quickly.
Peptide businesses are not untouchable. They are poorly served by generic onboarding and category-blind processing. The solution is not to disguise the business. It is to have it assessed properly and build the payment setup around the operation that actually exists.
